AU657866B2 - Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate and the production of the same - Google Patents

Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate and the production of the same

Info

Publication number
AU657866B2
AU657866B2 AU44227/93A AU4422793A AU657866B2 AU 657866 B2 AU657866 B2 AU 657866B2 AU 44227/93 A AU44227/93 A AU 44227/93A AU 4422793 A AU4422793 A AU 4422793A AU 657866 B2 AU657866 B2 AU 657866B2
Authority
AU
Australia
Prior art keywords
production
crystalline hydrate
triazolylthiomethylthio
same
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU44227/93A
Other languages
English (en)
Other versions
AU4422793A (en
Inventor
Yutaka Ide
Hisanori Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU4422793A publication Critical patent/AU4422793A/en
Application granted granted Critical
Publication of AU657866B2 publication Critical patent/AU657866B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU44227/93A 1992-07-31 1993-07-28 Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate and the production of the same Ceased AU657866B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31
JP4-204965 1992-07-31

Publications (2)

Publication Number Publication Date
AU4422793A AU4422793A (en) 1994-02-03
AU657866B2 true AU657866B2 (en) 1995-03-23

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44227/93A Ceased AU657866B2 (en) 1992-07-31 1993-07-28 Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate and the production of the same

Country Status (23)

Country Link
US (1) US5407929A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0581552B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100245938B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1037683C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE165360T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU657866B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9303235A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2101502A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69318077T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2115725T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI933391A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3026699T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU219637B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL106516A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9304611A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO303734B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ248285A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH30109A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL172835B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2118959C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA37181C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA935529B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1953162B9 (de) * 2001-02-24 2012-10-31 Boehringer Ingelheim Pharma GmbH & Co. KG Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
DE202004021379U1 (de) 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Kristalline Formen von Pitivastatin Calcium
SI1606293T1 (sl) 2003-03-27 2009-10-31 Basilea Pharmaceutica Ag Cefalosporin v kristalni obliki
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2016079A1 (de) 2006-05-04 2009-01-21 Boehringer Ingelheim International GmbH Polymorphe
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5769966B2 (ja) * 2007-08-17 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Fab関連疾患治療用プリン誘導体
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
ES2764251T3 (es) * 2008-08-15 2020-06-02 Boehringer Ingelheim Int Inhibidores de DPP-4 para uso en el tratamiento de curación de heridas en pacientes diabéticos
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
EP3366304B1 (en) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dpp−4阻害薬の医学的使用
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
KR940005636A (ko) 1994-03-22
AU4422793A (en) 1994-02-03
NO932745L (no) 1994-02-01
FI933391L (fi) 1994-02-01
NO932745D0 (no) 1993-07-30
NO303734B1 (no) 1998-08-24
TW307769B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-06-11
US5407929A (en) 1995-04-18
PL172830B1 (pl) 1997-12-31
DE69318077D1 (de) 1998-05-28
DE69318077T2 (de) 1998-10-29
IL106516A0 (en) 1993-11-15
MX9304611A (es) 1994-02-28
FI933391A7 (fi) 1994-02-01
ATE165360T1 (de) 1998-05-15
HU219637B (hu) 2001-06-28
HUT68602A (en) 1995-06-28
NZ248285A (en) 1994-07-26
CA2101502A1 (en) 1994-02-01
PH30109A (en) 1996-12-27
CN1089948A (zh) 1994-07-27
EP0581552A3 (en) 1994-06-01
CN1037683C (zh) 1998-03-11
KR100245938B1 (ko) 2000-04-01
BR9303235A (pt) 1994-03-01
IL106516A (en) 1998-06-15
ZA935529B (en) 1994-02-24
PL172835B1 (pl) 1997-12-31
ES2115725T3 (es) 1998-07-01
HU9302194D0 (en) 1993-10-28
EP0581552B1 (en) 1998-04-22
FI933391A0 (fi) 1993-07-29
EP0581552A2 (en) 1994-02-02
GR3026699T3 (en) 1998-07-31
RU2118959C1 (ru) 1998-09-20
UA37181C2 (uk) 2001-05-15
PL299870A1 (en) 1994-02-07

Similar Documents

Publication Publication Date Title
AU657866B2 (en) Triazolylthiomethylthio cephalosporin hydrochloride, its crystalline hydrate and the production of the same
AU616838B2 (en) N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro- 2h-benzopyran or dihydrobenzodioxin)carboxamide derivatives
AU6787690A (en) Amino acid derivatives
AU1025795A (en) Prolineamide derivatives
AU4236889A (en) Imidazoline derivative and preparation thereof
MY104937A (en) Cephalosporin derivatives and processes for their preparation
IL91001A0 (en) N-alkyl derivatives of antibiotic bu-3608 complex and pharmaceutical compositions containing them
IE880503L (en) Crystallized cephem-acid addition salts, and a process for the preparation thereof
CA2099692A1 (en) Process for preparing cephalosporin intermediates
EP0416810A3 (en) Cephalosporin compounds, process for their preparation, pharmaceutical compositions and intermediates
EP0416814A3 (en) Cephalosporin compounds, process for their preparation, pharmaceutical compositions and intermediates
AU6496886A (en) Cephalosporin derivatives and a process for their preparation
HUT53654A (en) Process for producing cefemcarboxylic acid compounds and pharmaceutical compositions comprising such compounds
AU2776389A (en) Beta-lactam antibiotics, processes for their preparation and their use as and in medicaments
AU6059094A (en) Active compound from a sponge
EP0390099A3 (de) Polare Cephalosporinderivate und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired